Highly efficient semi-solid and well-based fusion options provide rapid delivery of antibodies that are comparable to yields of manual single B cell platforms.
Hybridomas are produced by combining isolated primary B cells with myeloma cells in a proprietary fusion step.
Semi-solid: Selected using a semi-solid, media-based robotic clone picking system. After initial testing, supernatant from the best clones are provided to the client for testing on the intended assay. In almost all cases, semi-solid media derived clones can be characterized as monoclonal, negating the need for the sub-cloning step and reducing the development schedule by four to eight weeks.
Well-based: Selected using traditional plate-based cloning procedures. After initial testing, supernatant from the best clones are provided to the client for testing on the intended assay. Selected hybridoma clones will be sub-cloned via limited dilution or by semi-solid clone picking. The clones will be screened over several rounds of additional cell passages to ensure stability and clonality.